Natco Pharma (Canada) announces the launch of Nat-Lenalidomide capsules, the first generic alternative to Revlimid

Natco Pharma

1 September 2021 - Nat-Lenalidomide expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes.

Natco Pharma (Canada) announced today the launch of Nat-Lenalidomide capsules, the first generic alternative to Revlimid to be approved by Health Canada.

Read Natco Pharma press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Canada , Generic medicine